Arcus Biosciences stock extends recent pullback as technical signals favor stabilization

Arcus Biosciences stock extends recent pullback as technical signals favor stabilization
Arcus Biosciences slides 6.20% today

Arcus Biosciences celebrated its recent recognition on the New York Stock Exchange trading floor. The company acknowledged its team's achievements following the publication of ARC-20 trial data in Nature.

Highlights

  • RCUS continues to trade in a strong uptrend, currently positioned near the upper third of its 52-week range.
  • After last week’s $2.08 (6.7%) decline and a 6.2% drop today, the stock is undergoing a short-term corrective phase.
  • Key technicals signal overbought conditions and waning momentum, but strong trend support favors high probability of stabilization or rebound within the $28.44–$29.62 range.

Arcus Biosciences expressed gratitude for the recognition related to the Nature publication. The announcement included a link for readers to learn more about the research.

Bullish trend confirmed as price holds above key technical support

RCUS is trading at $28.92, holding firmly above the MA-20 ($25.80), MA-50 ($25.16), and MA-200 ($21.58) levels. This placement confirms a strong bullish trend across short-, medium-, and long-term timeframes. The Ichimoku Kijun on D1 is at $26.79, serving as immediate support below current prices. Near-term support sits at the Ichimoku Kijun ($26.79), with key support at MA-50 ($25.16). Near-term resistance is at MA-5 ($30.39). The next key resistance is found at MA-5 ($30.39) as the closest actionable moving average above price.

Mixed momentum signals as overbought readings meet recent pullback

Momentum indicators on D1 reveal a mixed picture: MACD signals Buy but ADX at 17.28 remains in neutral territory, indicating lackluster trend strength. RSI is elevated at 73.28, while both CCI (140.28) and Stoch RSI (94.95) are in overbought zones, pointing to stretched short-term conditions. BBP (3.81, Overbought) suggests buyer dominance intraday, but this is offset by several oscillators entering overbought or oversold readings. The Awesome Oscillator aligns with the bullish trend. RCUS has fallen $2.08 (6.71%) over the past week, currently trading below the previous weekly close of $31.00. The price is positioned in the lower part of the weekly range, with recent volatility at 13.36%. This week reflects a steady pullback from recent highs, with the technical outlook showing momentum divergences as overbought readings clash with waning trend strength. In today’s session, RCUS is down 6.20%, extending the short-term correction from last week’s high.

Upside bias favored as limited downside risk meets strong trend

Looking ahead, the expected range for RCUS over the next week is $28.44 to $29.62. Based on weekly RSI, ADX, MACD, and MA-50 (all Buy on W1), there is a very high probability (more than 80%) for price stabilization or a potential rebound, while the likelihood of a further decline is very low. The baseline scenario favors sideways movement within this corridor. A bullish scenario would see a breakout above $30.39, targeting further upside toward the yearly high of $31.74. Conversely, a bearish break below $26.79 support could trigger testing of the lower $25.16–$26.00 area, though downside risk is limited by strong trend signals on the weekly timeframe. This projected range sits near the upper third of the 52-week spectrum, underscoring how RCUS remains in a broad uptrend despite recent pullback.

Previously it was reported that Arcus Biosciences demonstrated sustained bullish momentum, with analyst outlooks favoring further upside despite short-term volatility. As the current article discusses the evolving technical landscape, traders should focus on emerging shifts in trend strength that could create new trading opportunities in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.